Blood will be collected at intervals and plasma separated and analyzed

Pharmacokinetics of LCZ696 (AHU377, LBQ657, valsartan) and Valsartan: Time to reach the maximum concentration after drug administration (Tmax) [ Time Frame: Day 1 and day 28 of treatment ] [ Designated as safety issue: No ]

Blood will be collected at intervals and plasma separated and analyzed

Pharmacokinetics of LCZ696 (AHU377, LBQ657, valsartan) and Valsartan:Area under the plasma concentration-time curve from time zero to 24 hours (AUC0-24 hours) [ Time Frame: Day 1 and day 28 of treatment ] [ Designated as safety issue: No ]

Blood will be collected at intervals and plasma separated and analyzed

Pharmacokinetics of LCZ696 and valsartan: Accumulation ratio between Day 28 and Day 1 [ Time Frame: Day 1 and day 28 of treatment ] [ Designated as safety issue: No ]

Blood will be collected at intervals and plasma separated and analyzed and the ratio AUC-24 hr(Day28) / AUC-24 hr(Day1) calculated

Mean seated blood pressure following 4 weeks of treatment [ Time Frame: Day 1 and day 28 of treatment ] [ Designated as safety issue: No ]

Seating BP (systolic blood pressure (msSBP) and diastolic blood pressure (msDBP))measurements will be performed at trough(immediately prior to dosing at the clinic). Arterial BP readings will be made with an automated BP device.

Mean arterial pressure (MAP) after following 4 weeks of treatment [ Time Frame: Day 1 and day 28 of treatment ] [ Designated as safety issue: No ]

Seating BP (systolic blood pressure (msSBP) and diastolic blood pressure (msDBP))measurements will be performed at trough(immediately prior to dosing at the clinic). Arterial BP readings will be made with an automated BP device.

Mean siting pulse pressure after 4 weeks of treatment. [ Time Frame: Day 1 and day 28 of treatment ] [ Designated as safety issue: No ]

Seating BP (systolic blood pressure (msSBP) and diastolic blood pressure (msDBP))measurements will be performed at trough(immediately prior to dosing at the clinic). Arterial BP readings will be made with an automated BP device.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01681576